# Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.

> **NCT00209612** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Hokkaido Gastrointestinal Cancer Study Group** · enrollment: 40 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Taxol
- **DRUG:** Campt, Topotesin

## Key facts

- **NCT ID:** NCT00209612
- **Lead sponsor:** Hokkaido Gastrointestinal Cancer Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2004-04
- **Primary completion:** 2008-11
- **Final completion:** 2009-03
- **Target enrollment:** 40 (ESTIMATED)
- **Why stopped:** due to strong side effect
- **Last updated:** 2009-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00209612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00209612, "Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00209612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*